Research Report Screener Results

Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results As of 10-Feb-2010
New Screen

All Reports | Brokerage Reports | Independent Reports

All Reports (Showing 1 to 10 of 18)

Release
Date Contributor Author Title Pages Price StarMine Author Rating More Info

EPS Accuracy * Portfolio Return **
9-Feb-10 ValuEngine, Inc. N/A ValuEngine Industry Report for BIOTECHNOLOGY 18 $49 View Abstract
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for ARYX 13 $25 View Abstract
8-Feb-10 PriceTarget Research, Inc. N/A ARYx Therapeutics has a current Overall Rating of F (Lowest Rating). 7 $25 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. 65 $20 View Abstract
6-Feb-10 Standard & Poor's Quantitative Report N/A ARYx Therapeutics 6 $25 View Abstract
6-Feb-10 Pechala's Reports Frantisek Pechala ARYS THERAPEUTICS INC (ARYX=US) 12-months forecast 1 $15 View Abstract
6-Feb-10 Pechala's Reports Lubomir Pechala ARYS THERAPEUTICS INC (ARYX=US) 2-weeks forecast 1 $10 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: ARYX THERAPEUTIC -- ARYX 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ARYX , DSCO , HEPH , ICGN , MSHL , OGXI , PIP , SOMX -- DRUGS 3 $4 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ARYX THERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
Next 8

Independent Reports (Showing 1 to 10 of 18)

Release
Date Contributor Author Title Pages Price More Info
9-Feb-10 ValuEngine, Inc. N/A ValuEngine Industry Report for BIOTECHNOLOGY 18 $49 View Abstract
8-Feb-10 ValuEngine, Inc. N/A ValuEngine Detailed Valuation Report for ARYX 13 $25 View Abstract
8-Feb-10 PriceTarget Research, Inc. N/A ARYx Therapeutics has a current Overall Rating of F (Lowest Rating). 7 $25 View Abstract
7-Feb-10 PriceTarget Research, Inc. N/A Drug Intelligence Monitor: overall outlook NEUTRAL - 25 new Leaders; 25 new Laggards. 65 $20 View Abstract
6-Feb-10 Standard & Poor's Quantitative Report N/A ARYx Therapeutics 6 $25 View Abstract
6-Feb-10 Pechala's Reports Frantisek Pechala ARYS THERAPEUTICS INC (ARYX=US) 12-months forecast 1 $15 View Abstract
6-Feb-10 Pechala's Reports Lubomir Pechala ARYS THERAPEUTICS INC (ARYX=US) 2-weeks forecast 1 $10 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Value Graph: ARYX THERAPEUTIC -- ARYX 1 $4 View Abstract
5-Feb-10 Ford Investor Services, Inc. N/A Industry Value Graph: ARYX , DSCO , HEPH , ICGN , MSHL , OGXI , PIP , SOMX -- DRUGS 3 $4 View Abstract
5-Feb-10 Jefferson Research N/A Jefferson Research Financial Sonar Report. A detailed analysis of the current fundamental performance of ARYX THERAPEUTICS INC including Earnings Quality, Cash Flow Quality, Operating Efficiency, Balance Sheet Quality and Valuation. 11 $20 View Abstract
Next 8

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.